Sarah Howell, Ph.D., Chief Executive Officer and Executive Director
Sarah Howell has been Chief Executive Officer of Arecor since 2015.
Susan Lowther, Chief Financial Officer and Executive Director/Company Secretary
Susan Lowther was appointed Chief Financial Officer and Company Secretary at Arecor in 2019. She brings significant financial leadership experience across a broad range of public and private life science companies.
Jan Jezek, Ph.D., Chief Scientific Officer
Jan Jezek has been Chief Scientific Officer of Arecor since 2007 and has led R&D for the proprietary protein stabilisation technologies of the company’s Arestat™ platform and their application to commercial therapeutic products. Jan is responsible for R&D activities, platform development and IP strategy.
Manjit Rahelu, Ph.D., Chief Business Officer
Manjit is an accomplished strategic deal maker, with a strong scientific background and over 25 years of technical, commercial and financial experience across large and mid-sized pharmaceutical and biotechnology companies.
David Gerring, Senior VP, Development
David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is VP, Development at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.
Helen Parris, Senior VP, Commercial and General Manager of Tetris Pharma Ltd
Helen has over 20 years of scientific, commercial and government affairs experience across several international biopharmaceutical companies. Before joining Tetris Pharma, Helen served as General Manager of Northern Markets (UK, Netherlands and Nordics) at Albireo Pharma, Inc., which was acquired by Ipsen in March 2023 and where she played a key role in establishing and building the regional affiliate.